Middle segment preserving pancreatectomy versus total pancreatectomy: a comparative analysis of short- and long-term outcomes
- PMID: 39653862
- DOI: 10.1007/s00595-024-02973-0
Middle segment preserving pancreatectomy versus total pancreatectomy: a comparative analysis of short- and long-term outcomes
Abstract
Purpose: Middle-segment preserving pancreatectomy (MSPP) serves as an alternative to total pancreatectomy (TP) for preserving the pancreatic body in multifocal pancreatic neoplasms. Despite the potential benefits of TP, the detailed short- and long-term prognoses remain unclear. We evaluated the feasibility of MSPP by comparing the perioperative outcomes and postoperative endocrine and exocrine functions with those of TP.
Methods: The study included 10 TP and 7 MSPP patients. Patients with pancreatic ductal adenocarcinoma and invasive intraductal papillary mucinous carcinoma were excluded.
Results: MSPP was associated with a high incidence (57.1%) of postoperative pancreatic fistula (POPF); however, there were no cases of post-pancreatectomy hemorrhage or postoperative mortality in any group. The postoperative hospital stay and readmission rates were comparable between the groups. At 1 year postoperatively, MSPP reduced the risk of new-onset insulin-dependent diabetes mellitus, maintained good glycemic control with minimal hypoglycemic events, and preserved skeletal muscle, subcutaneous fat, and visceral fat. One patient in the MSPP group with a neuroendocrine tumor had postoperative recurrence in the para-aortic lymph node.
Conclusions: Despite the high POPF rate and oncologic limitations, MSPP showed superior long-term outcomes in glycemic control and preservation of body composition. MSPP may be an acceptable treatment option for selected patients.
Keywords: Body composition; Diabetes mellitus; Pancreatectomy; Postoperative complications; Total pancreatectomy.
© 2024. The Author(s) under exclusive licence to Springer Nature Singapore Pte Ltd.
Conflict of interest statement
Declarations. Ethical approval: This study was approved by the Human Research Ethics Committee of the Tokyo Medical and Dental University (M2000-1080-06). Informed consent was obtained from all the participants included in this study. Conflict of interest: The authors declare no conflicts of interest in association with the present study.
References
-
- Tattersall RB. Brittle diabetes revisited: the Third Arnold Bloom Memorial Lecture. Diabet Med. 1997;14(2):99–110. https://doi.org/10.1002/(SICI)1096-9136(199702)14:2%3c99::AID-DIA320%3e3... . - DOI - PubMed
-
- Maker AV, Sheikh R, Bhagia V, Diabetes Control and Complications Trial (DCCT) Research Group. Perioperative management of endocrine insufficiency after total pancreatectomy for neoplasia. Langenbecks Arch Surg. 2017;402(6):873–83. https://doi.org/10.1007/s00423-017-1603-8 . - DOI - PubMed
-
- Kahl S, Malfertheiner P. Exocrine and endocrine pancreatic insufficiency after pancreatic surgery. Best Pract Res Clin Gastroenterol. 2004;18(5):947–55. https://doi.org/10.1016/j.bpg.2004.06.028 . - DOI - PubMed
-
- Petrides AS, DeFronzo RA. Glucose metabolism in cirrhosis: a review with some perspectives for the future. Diabetes Metab Rev. 1989;5(8):691–709. https://doi.org/10.1002/dmr.5610050805 . - DOI - PubMed
-
- Heidt DG, Burant C, Simeone DM. Total pancreatectomy: indications, operative technique, and postoperative sequelae. J Gastrointest Surg. 2007;11(2):209–16. https://doi.org/10.1007/s11605-006-0025-7 . - DOI - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
